SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.
Evercore ISI Group Initiates Coverage of SpringWorks Therapeutics (SWTX) with Outperform Recommendation
Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) with a Outperform recommendation. Analyst Price Forecast Suggests 84.32% Upside As of October 22,
Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference
Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1x1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference,
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.
Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference
Capsida Biotherapeutics ("Capsida"), a leading fully integrated next-generation gene therapy company developing treatments for rare and common diseases across all ages, today announced that the company will present at the 7(th) Annual Evercore HealthCONx Conference being held December 3-5,
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
Seeking Alpha1d
Finding Winners In Biotech, Probably The Riskiest Sector
Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...
bovnews11d
The SpringWorks Therapeutics Inc Enigma: What’s Causing the Wild Swings in SWTX Stock?
On Thursday, SpringWorks Therapeutics Inc (SWTX) stock saw a modest uptick, ending the day at $36.55 which represents a slight increase of $1.84 or 5.30% from the prior close of $34.71. The stock ...
ETF Daily News1d
Massachusetts Financial Services Co. MA Acquires 108,109 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The ...
Vertex leads J.P. Morgan's top biotech picks list for 2025
J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...
Insider Monkey4d
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined ...
Business Insider15d
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial ...